FDA CRL Forces Corcept Therapeutics to Reassess Relacorilant Development; Investor Probes Launched

Regulatory setback forces reassessment of relacorilant development plans

Corcept Therapeutics faces a fresh regulatory hurdle after the U.S. Food and Drug Administration issues a Complete Response Letter for relacorilant’s New Drug Application as a treatment for hypertension secondary to hypercortisolism. The agency acknowledges that Corcept’s pivotal GRACE trial meets its primary endpoint and says data from the GRADIENT trial provide confirmatory evidence, but it concludes it cannot reach a favorable benefit‑risk assessment without additional evidence of effectiveness. The CRL focuses regulatory attention on the adequacy of the efficacy dataset and the need for further demonstration that relacorilant delivers clinically meaningful blood‑pressure benefits in the target population.

The CRL compels Corcept to consider several development options, including additional clinical studies, targeted analyses of existing datasets, or detailed subgroup and responder analyses to clarify treatment effects. Company executives are likely engaging with the FDA to define a viable pathway forward — whether that means a new randomized trial, enrichment of patient selection criteria, extended follow‑up for durability of response, or prespecified secondary endpoint demonstration. The agency’s request for extra evidence shifts the program from a near‑regulatory decision point back into a period of data generation and regulatory negotiation.

The regulatory outcome also influences Corcept’s broader development strategy for relacorilant and its portfolio planning for hypercortisolism‑related indications. A requirement for more evidence may alter timelines for potential approval and commercial preparation, and it raises questions about optimal trial design, endpoints that capture clinically meaningful antihypertensive effects, and the role of confirmatory versus supportive datasets. Corcept’s next communications and interactions with the FDA will be pivotal in shaping the scope and duration of any additional studies the agency requires.

Law firms launch securities investigations

In response to the CRL disclosure, two national litigation firms — DJS Law Group and The Schall Law Firm — announce independent investigations into whether Corcept made false or misleading statements or failed to disclose material information to investors. Both firms say they are reviewing public statements, SEC filings and the timing of disclosures and invite shareholders who suffered losses to contact them for potential representation, noting these inquiries may be considered attorney advertising.